Bank of New York Mellon Corp Sells 82,891 Shares of Charles River Laboratories International, Inc. $CRL

Bank of New York Mellon Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 20.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 332,234 shares of the medical research company’s stock after selling 82,891 shares during the quarter. Bank of New York Mellon Corp’s holdings in Charles River Laboratories International were worth $66,274,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Tema Etfs LLC acquired a new position in Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC raised its position in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares in the last quarter. Activest Wealth Management raised its position in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. Geneos Wealth Management Inc. raised its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Charles River Laboratories International during the fourth quarter valued at approximately $46,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 1.9%

Shares of NYSE:CRL opened at $190.07 on Wednesday. The company has a fifty day moving average of $172.42 and a 200-day moving average of $182.07. The company has a market capitalization of $9.16 billion, a PE ratio of -50.55, a price-to-earnings-growth ratio of 2.13 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 52-week low of $143.06 and a 52-week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the previous year, the firm posted $2.34 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of several research analyst reports. Barclays boosted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $208.50.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.